TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01590849
Drug: Contraceptives, Oral, Combined (Yaz®)
Approvals — FDA: no, EMA: no, PMDA: no
Description: After a counseling session concerning the advantages, disadvantages and side effects of contraceptive methods (COC or nonhormonal methods), the volunteers were divided into two study groups according to the method they chose to use as follows:~* Case group: healthy women, users of COC containing 20 mcg ethynil estradiol and 3 mg drospirenone , 24 days of active pills, 4 days of pill-free interval (n=40).~* Control group: healthy women, users of nonhormonal methods of contraception (condoms or copper IUD) (n=40).~Subjects were tested once before the introduction of the contraceptive method and again after 6 months of its use.
Study: NCT01554163
Drug: Etoricoxib 30 mg
Normalized name: Etoricoxib 30 mg oral tablet
DrugBank: Etoricoxib (DB01628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoricoxib 30 mg tablet once daily for 12 weeks.
Study: NCT01554163
Drug: Celecoxib 200 mg
Normalized name: celecoxib 200 MG
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celecoxib 200 mg once daily for 12 weeks
Study: NCT02427802
Drug: Gentamicin collagen sponge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Up to 4 topical Gentamicin Collagen Sponges each containing 50 mg of gentamicin sulfate (equivalent to 32.5 mg of gentamicin base)
Study: NCT00937092
Drug: low-dose dopamine + low-dose furosemide
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: low-dose furosemide combined with low-dose dopamine (LDFD, furosemide 5 mg/h plus dopamine 5μg/kg/min intravenously)
Study: NCT03010241
Drug: Tangbi (prescription)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A kind of Granule(Tang bi fang) was made from five kind of Chinese herbs. Other: Standard medical care Standard medical care is in accordance with China Guideline for type 2 diabetes (2013).
Study: NCT03010241
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granule(Placebo) is in accordance with Tangbi prescription in appearance, colour, taste.~Other: Standard medical care. Standard medical care is in accordance with China Guideline for type 2 diabetes (2013).
Study: NCT02232555
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00481013
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: For six months, pts are randomized into placebo or treatment. After 6 months, all pts are on treatment
Study: NCT00516490
Drug: Na Cl %0.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 ml sterile saline subcutaneous injection on the 3rd day after embryo transfer
Study: NCT01281943
Drug: Temsirolimus 25mg and Pegylated liposomal doxorubicin 25mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temsirolimus 25mg IV on days 1, 8, 15 and 22 of each 28 day cycle~Pegylated liposomal doxorubicin 25mg/m2 IV on day 1 of each 28 day cycle
Study: NCT00224406
Drug: Repertaxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: An initial 'loading dose' of repertaxin was administered over 30 minutes by intravenous infusion followed by a maintenance dose lasting 47.5 hours.The infusion was to start approximately 2 hours prior to the anticipated time of reperfusion and was to continue during the ICU/hospital stay. The study medication was administered as a continuous intravenous infusion into a (high flow) central vein, by an infusion pump adequate to provide reliable infusion rates , as per treatment schedule. Total infusion volume was not to exceed 500 mL/24 hours.
Study: NCT02954458
Drug: TED
Normalized name: Meted
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05 mg/kg SC injection once daily.
Study: NCT00095459
Drug: BAY 43-9006
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00307853
Drug: Traumeel S
Normalized name: Traumeel S Injection Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients will receive an intra-operative injection of either Traumeel S or placebo solution. Afterwards, verum or indistinguishable placebo tablets, PO, two tablets five times daily from day 0 to 6 post-operatively, and two tablets three times daily from day 7 until day 21. To the extent possible, administration of tablets should be equally spaced between morning and evening (e.g. every 6 hours) at the same time every day.
Study: NCT01147003
Drug: Investigational new drug, company code: BGG492
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01147003
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00639392
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive a single dose of placebo administered by vein over about 15 minutes. Placebo is mostly water without Zoledronic Acid.
Study: NCT00639392
Drug: Zoledronic Acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients will receive a single dose of Zolendronic Acid. Zoledronic Acid is administered by vein over about 15 minutes.
Study: NCT02083653
Drug: Sym004 (12 mg/kg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sym004 is a 1:1 mixture of two mAbs (futuximab and modotuximab) which bind to two non-overlapping epitopes of the EGFR.
Study: NCT02083653
Drug: Sym004 (9/6 mg/kg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sym004 is a 1:1 mixture of two mAbs (futuximab and modotuximab) which bind to two non-overlapping epitopes of the EGFR.
Study: NCT00688545
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Non-interventional: Treatment assignment as per treating physician's judgement
Study: NCT02083653
Drug: Fluorouracil (5-FU)
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-FU will be administered at doses and schedules as per Investigator's discretion and in line with the local package insert.
Study: NCT02083653
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine will be administered at doses and schedules as per Investigator's discretion and in line with the local package insert.
Study: NCT00940641
Drug: AZD7325
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV Dose
Study: NCT00940641
Drug: AZD7325
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral dose
Study: NCT04876976
Drug: Cyanoacrylate, Isobutyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: using cyanoacrylate in the surgical repair of urethro-cutaneous fistula
Study: NCT00897975
Drug: phytosterol
Normalized name: Phytosterol
Approvals — FDA: no, EMA: no, PMDA: no
Description: phytosterol 450 mg 2 tabs bid with food
Study: NCT00897975
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT00688545
Drug: nsNSAIDs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-interventional: Treatment assignment as per treating physician's judgement
Study: NCT00282152
Drug: Optimal drug therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: The drugs used on this study are not investigational. They are drugs for Parkinson's disease that are standard of care. The drug form, dosage, frequency and duration will vary. Examples of drugs used include carbidopa/levodopa, pramipexole, ropinirole, and selegiline.
Study: NCT02929134
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Once daily tablet for 6 weeks: Doxycycline hyclate 200 mg per day x 6 weeks for patients \>50 kg or 100 mg per day for patients \<50 kg)
Study: NCT02929134
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily tablet for 6 weeks: matching tablets containing no active ingredients
Study: NCT03391804
Drug: ALLN-177
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALLN-177 7,500 units (2 capsules) with each meal/snack by mouth 5 times per day for 12 weeks
Study: NCT00752869
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: one tablet per day for 1 year
Study: NCT00856843
Drug: BLI800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for oral administration prior to colonoscopy
Study: NCT01892904
Drug: EE20/DRSP(BAY86-5300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet \[0.02 mg of ethinylestradiol (β-CDC) and 3 mg of drospirenone\] / day
Study: NCT02035553
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, two tablets, once daily by mouth
Study: NCT03019991
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASC 08 Placebo administered orally 100mg QD on day 1, day 4 and day 14; 100mg BID on day 5 -day 13
Study: NCT03358706
Drug: Caffeine 100 mg
Normalized name: caffeine 100 MG
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive 100 mg tablet of caffeine as a component of the Cytochrome P 450 probe cocktail orally.
Study: NCT03825068
Drug: general anesthetic
Normalized name: General anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: patient receive general anaesthetic only
Study: NCT01854697
Drug: ABT-450/r/ABT-267, ABT-333
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet; ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet
Study: NCT01014247
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of matching tablet
Study: NCT02335255
Drug: Placebo Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Topical Gel applied once daily for fourteen consecutive days to affected areas plus a 1/2 inch margin of healthy surrounding skin.
Study: NCT02946892
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be given for 12 weeks and then an exercise test will be performed
Study: NCT03257241
Drug: B arm (DAC)
Normalized name: Zodryl DAC
Approvals — FDA: no, EMA: no, PMDA: no
Description: After confirming the diagnosis, assuming the inclusion criteria and exclusion criteria are respected, the patients are randomized to one of two standard induction treatment protocols (A arm: DA-90 vs B arm: DAC). After completing induction I, an early bone marrow assessment is performed on day 14 from the beginning of the treatment (+ day 7 after finishing chemotherapy) using the cytological method and MRD is assessed by the immunophenotyping method. Therapeutic decision is taken on the basis of the cytological assessment. Patients, in whom the percentage of blasts in the bone marrow on day 14 is \> 10%, receive early induction II from day 16. An Immunophenotype test is a complementary examination.
Study: NCT03257241
Drug: B arm (FLAG-IDA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients who do not achieve CR after two courses of induction therapy or patients with relapsed leukemia are eligible for emergency treatment (salvage) according to the CLAG- M or FLAG-IDA protocol.
Study: NCT02342977
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will randomly receive placebo
Study: NCT01078298
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo tablets matched in appearance and dosage to varenicline tablets
Study: NCT03489941
Drug: Zaditor®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive one drop in one eye only based on the randomization list, one time over the course of the trial.
Study: NCT03489941
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive one drop in one eye only based on the randomization list, one time over the course of the trial.
Study: NCT03631654
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01653327
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02464865
Drug: Thiamine 1
Normalized name: thiamine 10 MG
DrugBank: Thiamine (DB00152)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: If severe symptoms and signs of thiamine deficiency are present, thiamine is prescribed.~Intervention 1 : severe symptom (heart failure, convulsion, or coma) : 50 mg thiamin administered very slowly intravenously, followed by a daily intramuscular dose of 10 mg for a week, and finally followed by 3-5 mg of thiamine per day orally for at least 6 weeks
Study: NCT02464865
Drug: Thiamine 2
Normalized name: thiamine 2 MG
DrugBank: Thiamine (DB00152)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: If symptoms and signs of thiamine deficiency are present, thiamine is prescribed.~If mild symptom : a daily oral dose of 10 mg thiamin during the first week, followed by 3-5 mg of thiamin per day orally for at least 6 weeks
Study: NCT00003215
Drug: CHOP regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00003215
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003215
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00003215
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003215
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003215
Drug: therapeutic hydrocortisone
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00750256
Drug: GSK1278863A
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK1278863A planned doses from 2mg to 450mg which may change based on safety or PK from previous cohorts.
Study: NCT00047788
Drug: ZD6474
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00047788
Drug: VEGF-receptor tyrosine kinase (KDR)
Normalized name: Tyrosine
DrugBank: Tyrosine (DB00135)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01738191
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03863691
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: A placebo capsule with no inert pharmacological effect. Looks identical to the amisulpride capsules.
Study: NCT04263038
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study drug without active agent
Study: NCT03597139
Drug: Restasis®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparator
Study: NCT04209439
Drug: Dexketoprofen-trometamol
Normalized name: dexketoprofen trometamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg Dexketoprofen-trometamol intravenous
Study: NCT01994473
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: single oral dose placebo
Study: NCT02737670
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet morning and evening for 40 days
Study: NCT01770067
Drug: CITA-RNPT
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02107950
Drug: Standard of Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carboplatin and Gemcitabine is Standard of Care First Line Chemotherapy
Study: NCT00467402
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03338569
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo designed to mimic intervention
Study: NCT01120132
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo solution administered during 28 days
Study: NCT03341117
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid 300 mg per capsule
Study: NCT03118479
Drug: Testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Androgel 7.5 g to be applied transdermally daily for 3 months.
Study: NCT03118479
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet to be taken daily for 3 months
Study: NCT03461302
Drug: Topical corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clobetasone butyrate 0.05% ointment
Study: NCT02169388
Drug: placebo（for probiotic）
Approvals — FDA: no, EMA: no, PMDA: no
Description: microbiota modulation using placebo
Study: NCT05049473
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate 1500 mg/m² IV 24h-infusion. Day 2. Cycles: A1, B1, C1 (1000 mg/m² if patient in CR) , A2 (1000 mg/m² if patient in CR), B2 (1000 mg/m² if patient in CR) , C2 (1000 mg/m² if patient in CR) Methotrexate 500 mg/m² IV 24h-infusion. Day 2. Cycles: A1\*, B1\*, A2\*, B2\*, A3\*, B3\*
Study: NCT05049473
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide 200 mg/m² IV in 1 hour. Days 1 to 5. Pre-phase. Cyclophosphamide 200 mg/m² IV in 1 hour. Days 2 to 6. Cycles: B1, B2, B1\*, B2\*, B3\*
Study: NCT05049473
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin 25 mg/m² IV in 15 min. Days 5 and 6. Cycles: B1/B1\*, B2, B2\*, B3\*
Study: NCT05049473
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate 12 mg IT. Day 1. Pre-phase Methotrexate 12 mg IT. Days 2 and 6. Cycles: A1, B1, A2, B2 Methotrexate 15 mg IT. Day 2. Cycles: A1\*, B1\*, A2\*, B2\*, A3\*, B3\*
Study: NCT05049473
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone 20 mg IT. Days 2 and 6. Cycles: A1, B1, A2, B2
Study: NCT04338191
Drug: mFOLFOXIRI adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: mFOLFOXIRI (oxaliplatin 85 mg/m2, irinotecan 150 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) for 6 cycles
Study: NCT04338191
Drug: mFOLFOX6 adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: mFOLFOXIRI (oxaliplatin 85 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 400mg/m2 infusion, and 2400mg/m2 as a 46-hour continuous infusion on day 1) for 6 cycles
Study: NCT04679948
Drug: Percoffedrinol®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet
Study: NCT04679948
Drug: Coumadin®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet
Study: NCT04679948
Drug: Antra MUPS®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gastro-resistant tablet
Study: NCT00028522
Drug: R(+)XK469
Normalized name: R
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT00650286
Drug: Provigil® Tablets 200 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200mg, single dose fed
Study: NCT03710369
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo pill was compounded by McDonalds Pharmacy.
Study: NCT02068859
Drug: Diclofenac Cream 8%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be given instructions to apply the study drug topically 3-4 times daily to the affected knee. Application instructions will also be printed on the tubes of products.
Study: NCT02068859
Drug: Diclofenac Gel 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be given instructions to apply the study drug topically 3-4 times daily to the affected knee. Application instructions will also be printed on the tubes of products.
Study: NCT05535322
Drug: SGLT2i
Approvals — FDA: no, EMA: no, PMDA: no
Description: SGLT2 inhibitors users with no GLP-1RA prescription: all T2D adults treated with Sodium/glucose cotransporter-2 inhibitors (SGLT2i) or initiating treatment with SGLT2i during the study period and who were not treated with a GLP-1RA
Study: NCT05535322
Drug: Miscellany
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other glucose-lowering agents users: all T2D adults who were not treated with GLP-1RA and/or SGLT2i and/or insulin during the study period and who were treated with other glucose-lowering agents during the study period
Study: NCT00233207
Drug: IC14
Normalized name: CATH,INTERMIT 14FR RELIAMED #PIC1416
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00671125
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramelteon placebo-matching tablets, orally, once nightly for up to 5 weeks.
Study: NCT01048086
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be given in the same manner as retinoic acid in capsules that look identical.
Study: NCT01004978
Drug: Doxorubicin Hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Undergo TACE
Study: NCT01004978
Drug: Doxorubicin-Eluting Beads
Approvals — FDA: no, EMA: no, PMDA: no
Description: Undergo TACE
Study: NCT02215499
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03749109
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo
Study: NCT00417144
Drug: Arvekap 0.1mg (Triptorelin, Ipsen, France)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01356329
Drug: Enoxaparin, Heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients who meet the Inclusion Criteria and signed an informed consent will be randomly assigned to 1 of the 2 treatment groups (the Enoxaparin (Group A) and Unfractionated Heparin (Group B)~). Subjects will be assigned consecutive study numbers according to a predetermined random code generated by the Biostatistician.
Study: NCT00661453
Drug: Valproic Acid and Levocarnitine
Normalized name: levocarnitine / picolinic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: Valproic Acid and Levocarnitine; syrup; dosage is by weight
Study: NCT02000882
Drug: BKM120
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04114656
Drug: GSK3858279
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK3858279 will be available as IV infusion and the dose level to be administered is 3 milligrams (mg) per kilogram (kg).
Study: NCT00642603
Drug: capecitabine [Xeloda]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg/m2 twice-daily, taken orally on Days 1-7 of each 2 week cycle
Study: NCT00259428
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration
Study: NCT03334422
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT04104997
Drug: 5% GLH8NDE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% GLH8NDE as eye drops
Study: NCT04104997
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo as eye drops
Study: NCT01716611
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00994214
Drug: BIM 23A760
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injections of BIM23A760 once a week. Until progression or unacceptable toxicity develops.
Study: NCT00153816
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo; two tablets per day